Acadian Asset Management
SYRE icon

Acadian Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Acadian Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-814
Closed -$23K – 2148
2024
Q3 		$23K Buy
+814
New +$22.7K ﹤0.01% 1961
2024
Q1 		– Sell
-1,169
Closed -$25K – 1780
2023
Q4 		$25K Sell
1,169
-10,719
-90% -$148K ﹤0.01% 1570
2023
Q3 		$145K Sell
11,888
-43,767
-79% -$579K ﹤0.01% 1247
2023
Q2 		$625K Hold
55,655
– – ﹤0.01% 996
2023
Q1 		$402K Hold
55,655
– – ﹤0.01% 1108
2022
Q4 		$625K Buy
55,655
+36,913
+197% +$663K ﹤0.01% 979
2022
Q3 		$245K Buy
18,742
+2,207
+13% +$27.3K ﹤0.01% 1164
2022
Q2 		$208K Buy
16,535
+10,559
+177% +$370K ﹤0.01% 1190
2022
Q1 		$342K Buy
5,976
+743
+14% +$62.4K ﹤0.01% 1088
2021
Q4 		$620K Buy
+5,233
New +$826K ﹤0.01% 954
2019
Q2 		– Sell
-343
Closed -$69K – 2030
2019
Q1 		$69K Buy
+343
New +$71.5K ﹤0.01% 1607
2018
Q4 		– Sell
-2,169
Closed -$519K – 1827
2018
Q3 		$519K Sell
2,169
-755
-26% -$176K ﹤0.01% 870
2018
Q2 		$773K Buy
2,924
+1,690
+137% +$416K ﹤0.01% 796
2018
Q1 		$307K Buy
1,234
+831
+206% +$150K ﹤0.01% 967
2017
Q4 		$54K Buy
403
+221
+121% +$27K ﹤0.01% 1214
2017
Q3 		$22K Buy
+182
New +$17.1K ﹤0.01% 1214
2017
Q1 		– Sell
-19
Closed -$2K – 1767
2016
Q4 		$2K Buy
+19
New +$2.77K ﹤0.01% 1572

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Acadian Asset Management's SYRE Position: Q4 2024 in Review

Acadian Asset Management sold out of Spyre Therapeutics (SYRE) in Q4 2024, closing a stake of 814 shares — an estimated $23K sold.

Acadian Asset Management first reported a position in SYRE in Q4 2016 and held it in 17 quarters. The position peaked at $773K in Q2 2018. 131 funds tracked by Wall St. Rank hold SYRE as of Q4 2024.

  • Acadian Asset Management reported no remaining Spyre Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 814 Spyre Therapeutics shares in Q4 2024, an estimated $23K.
  • Acadian Asset Management first reported a position in Spyre Therapeutics in Q4 2016 and held it in 17 quarters.
  • Acadian Asset Management's Spyre Therapeutics position peaked at $773K in Q2 2018.
  • 131 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.